for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

U.S. FDA approves Bristol Myers' combo therapy for lung cancer

May 15 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co’s therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck’s Keytruda.

The combination of Bristol's treatments, Opdivo and Yervoy, is approved for treating patients with non-small cell lung cancer, the FDA said here. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila and Shailesh Kuber)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up